---
title: SARS-CoV-2 antibody test moving to the next development phase
description: SARS-CoV-2 antibody test on high-throughput open-access clinical chemistry platforms.
---

Moss, 22.01.2021

Gentian Diagnostics AS is pleased to announce that its high-throughput  
SARS-CoV-2 antibody test project has moved from the proof-of-concept phase to  
the project initiation and optimisation phase. An official project plan has been  
established with an approved budget and a dedicated project team, moving the  
project forward. The timeline to launch is set to Q4 2021.

The aim for the SARS-CoV-2 antibody test is to offer the first assay on  
high-throughput open-access clinical chemistry platforms, that supports  
vaccination efforts and aid in community management by the determination of  
immunisation status.

The project is supported by the collaboration with Professor Ørjan Olsvik and  
Dr. Vegard Skogen at the University of Tromsø, The Arctic University of Norway,  
providing expertise and guidance regarding SARS-CoV-2 research and vaccination  
trends.

Gentian’s CEO Dr. Hilja Ibert commented: “This is truly an outstanding  
achievement. Our R&D team has managed to bring this marker into the optimisation  
phase in record time and with the participation from our collaborating partners  
we will move forward with the assay development."

**For further information contact:**

Hilja Ibert CEO, Gentian Diagnostics  
E-mail: hilja.ibert@gentian.no  
Cell Phone: +47 919 05 242

Njaal Kind CFO, Gentian Diagnostics  
E-mail: njaal.kind@gentian.no  
Cell Phone: +47 919 06 525

 

**MeldingsID:** 523005

### You may also read

[Jul 02, 2026 - Ole Sørlie](https://www.gentian.com/investor-relations-stock-information/investors-news/sars-cov-2-antibody-test#)

##### [Gentian Diagnostics: Invitation to presentation of second quarter results](https://www.gentian.com/investor-relations-stock-information/investors-news/gentian-diagnostics-invitation-to-presentation-of-second-quarter-results-1)

Gentian Diagnostics ASA will present its second quarter 2026 results on 9 July 2026 at 09.00 CEST. The..

[Read more](https://www.gentian.com/investor-relations-stock-information/investors-news/gentian-diagnostics-invitation-to-presentation-of-second-quarter-results-1)

[Jun 24, 2026 - Ole Sørlie](https://www.gentian.com/investor-relations-stock-information/investors-news/sars-cov-2-antibody-test#)

##### [ESSANGE REAGENTS AND GENTIAN DIAGNOSTICS ANNOUNCE COLLABORATION AGREEMENT](https://www.gentian.com/investor-relations-stock-information/investors-news/essange-reagents-and-gentian-diagnostics-announce-collaboration-agreement)

Amsterdam / Moss, 24 June 2026 ESSANGE REAGENTS AND GENTIAN DIAGNOSTICS ANNOUNCE COLLABORATION AGREEMENT..

[Read more](https://www.gentian.com/investor-relations-stock-information/investors-news/essange-reagents-and-gentian-diagnostics-announce-collaboration-agreement)

[May 29, 2026 - Ole Sørlie](https://www.gentian.com/investor-relations-stock-information/investors-news/sars-cov-2-antibody-test#)

##### [Mandatory notification of trade](https://www.gentian.com/investor-relations-stock-information/investors-news/mandatory-notification-of-trade-1780055230560)

Moss, 29 May 2026 Gentian Diagnostics ASA ("Gentian") has today been notified that the following transaction..

[Read more](https://www.gentian.com/investor-relations-stock-information/investors-news/mandatory-notification-of-trade-1780055230560)